

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

FAX RECEIVED

SEP 12 2002

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner M. Rao, fax number (703) 305-3014.

Respectfully submitted,

Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Date: September 12, 2002

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

AMENDMENT FEE TRANSMITTALCommissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed March 12, 2002.


It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from June 12, 2002 to September 12, 2002. The required fee for the extension is estimated to be \$920.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$920, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 12, 2002



Elias J. Lambins, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 5843.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schüle et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed March 12, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 1-26 without prejudice or disclaimer. Please add new claims 27-42:

27. An enzyme exhibiting beta-1,4-endoglucanase activity (EC 3.2.1.4) which has a temperature optimum of 65°C measured at a pH of 7.5 and an amino acid sequence that is at least 75% identical to amino acids 26-485 or 26-646 of SEQ ID NO: 10 wherein identity is determined by GAP provided in the GCG program package using a GAP creation penalty of 3.0 and GAP extension penalty of 0.1.

28. The enzyme of claim 27, which belongs to family 9 of glycosyl hydrolases.

29. The enzyme of claim 27, which has an amino acid sequence that is at least 85% identical to amino acids 26-485 or 26-646 of SEQ ID NO: 10.

30. The enzyme of claim 27, which has an amino acid sequence that is at least 90% identical to amino acids 26-485 or 26-646 of SEQ ID NO: 10.

31. The enzyme of claim 27, which has an amino acid sequence that is at least 95% identical to amino acids 26-485 or 26-646 of SEQ ID NO: 10.